NCT/Study#
NCT06661720 /
A032201
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma – STRIKE
DISEASE GROUP:
Genito-Urinary
current phase:
Phase III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
